Neuberger Berman Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.5M | Sell |
238,754
-4,503
| -2% | -$562K | 0.02% | 576 |
|
|
2025
Q4 | $29.7M | Sell |
243,257
-4,539
| -2% | -$520K | 0.02% | 573 |
|
|
2025
Q3 | $24.8M | Sell |
247,796
-4,797
| -2% | -$432K | 0.02% | 607 |
|
|
2025
Q2 | $20.9M | Sell |
252,593
-3,903
| -2% | -$311K | 0.02% | 639 |
|
|
2025
Q1 | $20.8M | Sell |
256,496
-1,094
| -0.4% | -$97.8K | 0.02% | 617 |
|
|
2024
Q4 | $23.2M | Sell |
257,590
-2,077
| -0.8% | -$201K | 0.02% | 622 |
|
|
2024
Q3 | $25.7M | Sell |
259,667
-1,299
| -0.5% | -$128K | 0.02% | 598 |
|
|
2024
Q2 | $24.2M | Buy |
260,966
+26,359
| +11% | +$2.36M | 0.02% | 593 |
|
|
2024
Q1 | $22.3M | Sell |
234,607
-11,590
| -5% | -$1.08M | 0.02% | 621 |
|
|
2023
Q4 | $22M | Buy |
246,197
+223,081
| +965% | +$16.6M | 0.02% | 599 |
|
|
2023
Q3 | $1.69M | Sell |
23,116
-1,140
| -5% | -$91.1K | ﹤0.01% | 1115 |
|
|
2023
Q2 | $2.02M | Sell |
24,256
-206
| -0.8% | -$17.2K | ﹤0.01% | 1082 |
|
|
2023
Q1 | $1.86M | Buy |
24,462
+301
| +1% | +$25K | ﹤0.01% | 1104 |
|
|
2022
Q4 | $2.01M | Sell |
24,161
-2,188
| -8% | -$177K | ﹤0.01% | 1069 |
|
|
2022
Q3 | $2.09M | Sell |
26,349
-5,105
| -16% | -$430K | ﹤0.01% | 1066 |
|
|
2022
Q2 | $2.34M | Sell |
31,454
-18,905
| -38% | -$1.42M | ﹤0.01% | 1075 |
|
|
2022
Q1 | $4.49M | Sell |
50,359
-8,034
| -14% | -$742K | ﹤0.01% | 986 |
|
|
2021
Q4 | $6.54M | Sell |
58,393
-1,881
| -3% | -$227K | 0.01% | 917 |
|
|
2021
Q3 | $7.58M | Buy |
60,274
+4,326
| +8% | +$557K | 0.01% | 870 |
|
|
2021
Q2 | $7.58M | Buy |
55,948
+8,778
| +19% | +$1.15M | 0.01% | 870 |
|
|
2021
Q1 | $6.4M | Buy |
47,170
+860
| +2% | +$129K | 0.01% | 908 |
|
|
2020
Q4 | $6.52M | Buy |
46,310
+4,015
| +9% | +$514K | 0.01% | 857 |
|
|
2020
Q3 | $4.71M | Buy |
42,295
+910
| +2% | +$102K | 0.01% | 870 |
|
|
2020
Q2 | $4.63M | Sell |
41,385
-8,835
| -18% | -$870K | 0.01% | 845 |
|
|
2020
Q1 | $3.89M | Buy |
50,220
+8,072
| +19% | +$715K | 0.01% | 822 |
|
|
2019
Q4 | $4.01M | Buy |
42,148
+18,278
| +77% | +$1.58M | ﹤0.01% | 896 |
|
|
2019
Q3 | $1.82M | Buy |
23,870
+600
| +3% | +$49.9K | ﹤0.01% | 1033 |
|
|
2019
Q2 | $2.04M | Buy |
23,270
+11,600
| +99% | +$989K | ﹤0.01% | 1030 |
|
|
2019
Q1 | $1.06M | Sell |
11,670
-6,760
| -37% | -$575K | ﹤0.01% | 1106 |
|
|
2018
Q4 | $1.32M | Buy |
18,430
+7,575
| +70% | +$610K | ﹤0.01% | 1055 |
|
|
2018
Q3 | $1.04M | Buy |
10,855
+8,355
| +334% | +$810K | ﹤0.01% | 1180 |
|
|
2018
Q2 | $238K | Hold |
2,500
| – | – | ﹤0.01% | 1601 |
|
|
2018
Q1 | $219K | Hold |
2,500
| – | – | ﹤0.01% | 1593 |
|
|
2017
Q4 | $212K | Sell |
2,500
-860
| -26% | -$72K | ﹤0.01% | 1675 |
|
|
2017
Q3 | $291K | Hold |
3,360
| – | – | ﹤0.01% | 1421 |
|
|
2017
Q2 | $259K | Sell |
3,360
-1,100
| -25% | -$78K | ﹤0.01% | 1455 |
|
|
2017
Q1 | $309K | Buy |
+4,460
| New | +$300K | ﹤0.01% | 1414 |
|
Other funds holding XBI
Neuberger Berman Group's XBI Position: Q1 2026 in Review
Neuberger Berman Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q1 2026, selling an estimated $562K and leaving 238,754 shares worth $30.5M. The position accounts for 0.02% of the portfolio, ranked #576.
Neuberger Berman Group first reported a position in XBI in Q1 2017 and has held it in 37 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Neuberger Berman Group held 238,754 shares of State Street SPDR S&P Biotech ETF worth $30.5M as of Q1 2026.
- Neuberger Berman Group sold 4,503 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $562K.
- State Street SPDR S&P Biotech ETF made up 0.02% of Neuberger Berman Group's portfolio in Q1 2026, its #576 holding.
- Neuberger Berman Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 37 quarters since.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.